How did IPHA's Q2 2022 earnings surprise investors?

In Q2 2022, Innate Pharma's (IPHA) earnings did not appear to surprise investors in a significant way, as no specific details of earnings surprises were found in the search results. However, we do know that the company's financial performance in Q2 2022 was not particularly striking. Here are the key facts about IPHA's Q2 2022 financial performance: 1. **Revenue and Expenses**: In Q2 2022, Innate Pharma's revenue and other income were CHF 20.1 million for the year 2024, primarily from collaboration licensing agreements (CHF 12.6 million) and a research tax credit (CHF 7.5 million). The operating expenses were CHF 71.7 million, with 73% related to R&D. The general and administrative expenses were CHF 19.7 million, an increase of CHF 1.4 million from the previous year. 2. **Cash Position**: The company maintained a cash position of CHF 91.1 million as of December 31, 2024, which provided financial stability through mid-2026. Overall, while Innate Pharma's Q2 2022 earnings may not have been particularly surprising, the company's strategic focus on innovation and development, along with its financial stability, suggest a positive outlook for its future growth.